Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. Magn Reson Med 2012 Oct;68(4):1266-72
Date
01/04/2012Pubmed ID
22213469Pubmed Central ID
PMC3323703DOI
10.1002/mrm.23315Scopus ID
2-s2.0-84866734674 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Frequently, bevacizumab is combined with chemotherapeutics such as irinotecan, motivated by studies showing improved clinical outcomes compared with historical controls. However, no systematic studies have been performed to determine if and how these drugs should be combined for optimal therapeutic response. The purpose of this study was to characterize the temporal combinations of bevacizumab and irinotecan by measuring the contrast-agent enhanced tumor volumes and relative cerebral blood volume using dynamic susceptibility contrast imaging. The studies, performed in the U87 brain tumor model, show a vascular normalization window with bevacizumab monotherapy and are consistent with clinical indications of no additional benefit in the addition of irinotecan to bevacizumab therapy.
Author List
Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KMAuthors
Shekar N. Kurpad MD, PhD Sr Associate Dean, Professor in the Neurosurgery department at Medical College of WisconsinKathleen M. Schmainda PhD Professor in the Biophysics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AnimalsAntibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Blood Volume
Blood Volume Determination
Brain Neoplasms
Camptothecin
Cell Line, Tumor
Cerebrovascular Circulation
Magnetic Resonance Imaging
Male
Rats
Rats, Nude
Reproducibility of Results
Sensitivity and Specificity
Treatment Outcome
